Intra-arterial Albumin Infusion After Endovascular Therapy for Stroke Patients

Launched by TIANJIN HUANHU HOSPITAL · Jul 12, 2023

Keywords

ClinConnect Summary

This clinical trial is looking at a new treatment for patients who have had a specific type of stroke called acute ischemic stroke. After these patients undergo a procedure to remove a blockage in their blood vessels (called thrombectomy), the researchers want to see if giving them a substance called albumin through their blood vessels can help them recover better. The study will check if this treatment is safe and how much albumin is the best amount to use.

To participate in this trial, patients must be between 18 and 80 years old and have had a successful thrombectomy for a stroke caused by a large blood vessel blockage. They should also have a certain level of stroke severity before treatment. Unfortunately, some people might not be able to join, such as those with heart or kidney issues, certain types of anemia, or allergies to albumin. If eligible, participants will receive the albumin treatment and be closely monitored by the medical team to ensure their safety throughout the trial. This study is not yet recruiting participants, but it aims to provide valuable insights for future stroke treatments.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. AIS patients with anterior circulation due to large vessel occlusion; 2. Age between 18 and 80 years; 3. Baseline NIHSS score ≥ 6; 4 .Successful recanalization after thrombectomy (mTICI grade ≥ 2b); 5. Written informed consent provided by the patients or their legal relatives.
• • .
• Exclusion Criteria:
• • 1. Upon admission, the patient's medical history and physical examination revealed manifestations indicative of congestive heart failure (CHF), such as jugular venous distention, the presence of a third heart sound, resting tachycardia at a rate of 100 beats per minute attributable to heart failure, hepatomegaly, and/or lower extremity edema attributable to heart failure or of unknown etiology;
• • 2. History of acute myocardial infarction within the preceding 3 months;
• • 3. The patient's medical history, electrocardiogram findings upon admission, or physical examination indicated the presence of second- or third-degree heart block or any arrhythmia associated with hemodynamic instability, as determined by the investigator's assessment;
• • 4. Acute or chronic renal failure with serum creatinine levels exceeding 2.0 mg/dL;
• • 5. Severe anemia characterized by a hematocrit below 32%;
• • 6. Computed tomography findings upon admission indicating the presence of any form of hemorrhage;
• • 7. Pregnancy status;
• • 8. Previous history of allergic reactions to albumin administration;
• • 9. Elevated blood pressure exceeding 185/110 mmHg when investigating the use of albumin administration;
• • 10. Presence of other potentially life-threatening medical conditions;
• • 11. Individuals with current chronic lung diseases, such as chronic obstructive pulmonary disease, bronchiectasis, or any other lung disorder that significantly impairs daily activities; 12. Individuals with known allergies to albumin.